Employees: 01 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2006-09-12 (19 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: RUEIL-MALMAISON (92500), Hauts-de-Seine
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL PHARMACIE LIEU-UNG : revenue, balance sheet and financial ratios
EURL PHARMACIE LIEU-UNG is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in RUEIL-MALMAISON (92500),
this company of category PME
shows in 2015 a revenue of 1.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE LIEU-UNG (SIREN 491961645)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
1 544 917 €
Net income
129 172 €
163 217 €
183 194 €
106 199 €
158 034 €
167 841 €
142 196 €
111 037 €
102 588 €
111 816 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
189 812 €
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
7.2%
Revenue and income statement
In 2024, EURL PHARMACIE LIEU-UNG generates positive net income of 129 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2024: 112 k€ -> 129 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
129 172 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 27%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 75%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
27.298%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
75.375%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
213.502
166.154
129.037
97.613
80.214
71.843
60.343
45.392
35.048
27.298
Financial autonomy
30.553
35.635
40.577
46.092
51.622
54.349
58.672
64.218
70.715
75.375
Repayment capacity
10.828
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
7.605%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
27.32024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good
In 2024, the debt ratio of EURL PHARMACIE LIEU-UNG (27.30) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
75.38%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent+7 pts over 3 years
In 2024, the financial autonomy of EURL PHARMACIE LIEU-UNG (75.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 651.46. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
161.061
146.906
133.77
143.869
248.065
377.567
365.433
373.575
559.442
651.455
Interest coverage
18.083
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
651.462024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Excellent
In 2024, the liquidity ratio of EURL PHARMACIE LIEU-UNG (651.46) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution EURL PHARMACIE LIEU-UNG
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
113 690 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
25
0
0
0
0
0
0
0
0
0
Customer payment term (days)
2
0
0
0
0
0
0
0
0
0
Supplier payment term (days)
20
0
0
0
0
0
0
0
0
0
Positioning of EURL PHARMACIE LIEU-UNG in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of EURL PHARMACIE LIEU-UNG is estimated at
1 803 336 €
(range 1 255 815€ - 2 697 894€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1255k€1803k€2697k€
1 803 336 €Range: 1 255 815€ - 2 697 894€
NAF 5 année 2024
Valuation method used
Net Income Multiple
129 172 €
×
14.0x
=1 803 337 €
Range: 1 255 815€ - 2 697 895€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE LIEU-UNG with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE LIEU-UNG
What is the revenue of EURL PHARMACIE LIEU-UNG ?
The revenue of EURL PHARMACIE LIEU-UNG in 2015 is 1.5 M€.
Is EURL PHARMACIE LIEU-UNG profitable?
Yes, EURL PHARMACIE LIEU-UNG generated a net profit of 129 k€ in 2024.
Where is the headquarters of EURL PHARMACIE LIEU-UNG ?
The headquarters of EURL PHARMACIE LIEU-UNG is located in RUEIL-MALMAISON (92500), in the department Hauts-de-Seine.
Where to find the tax return of EURL PHARMACIE LIEU-UNG ?
The tax return of EURL PHARMACIE LIEU-UNG is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE LIEU-UNG operate?
EURL PHARMACIE LIEU-UNG operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart